Status:
COMPLETED
Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging
Lead Sponsor:
Bayer
Conditions:
Magnetic Resonance Imaging
Eligibility:
All Genders
18+ years
Brief Summary
Patients will be recruited from those who will undergo contrast enhanced MRI. Safety and tolerability will be assessed.
Eligibility Criteria
Inclusion
- 18 years old and above undergoing contrast enhanced cranial or spinal MRI with Gadobutrol (Gadovist)
Exclusion
- History of hypersensitivity reaction to gadolinium containing contrast material
- Hypersensitivity to any of the ingredients of Gadobutrol (Gadovist)
- History of hypersensitivity to any other contrast agent
- Patients with uncorrected hypokalemia
- Pregnant and lactating women
- Patients with severe cardiovascular diseases
- Patients in whom MRI cannot be performed.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00905879
Start Date
June 1 2009
End Date
January 1 2011
Last Update
April 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Philippines